NDAINTRAVENOUSPOWDERPriority Review
Approved
Jul 2019
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
4/8 — Partial
Priority Review
RECARBRIO (imipenem anhydrous, cilastatin, and relebactam anhydrous) by Merck & Co. is dipeptidase inhibitors [moa]. First approved in 2019.
Drug data last refreshed 14h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RECARBRIO is a fixed-dose combination IV antibiotic containing imipenem, cilastatin, and relebactam—a novel β-lactamase inhibitor. It is indicated for serious gram-negative and gram-positive infections, including those resistant to standard carbapenems. The relebactam component inhibits serine β-lactamases, restoring imipenem efficacy against resistant pathogens.
$0.001BPart D
Peak6.4 years to LOEProduct is at peak lifecycle with minimal Medicare Part D penetration, suggesting limited commercial team expansion and a niche hospital-focused model.
Mechanism of Action
Dipeptidase Inhibitors
Pharmacologic Class:
Renal Dehydropeptidase Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
RECARBRIO is a niche, hospital-focused specialty antibiotic with minimal linked job postings, indicating a small, highly specialized commercial footprint. Career opportunities are concentrated in hospital/formulary access and infectious disease specialist engagement rather than broad field sales.
Hospital Account ManagerInfectious Disease Specialist (Sales)
Worked on RECARBRIO at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.